drugset / Trial / NCT06199427
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
Phase 2
Recruiting
100 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NaSingle-groupOpen-labelTreatment
Summary
The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)
Timeline
- Start
- 2023-11-21
- Primary completion
- 2026-11-21
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 25 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |
| Subject | Ruxolitinib | Small molecule | 7 mg/m2 | — |